The Trump administration is freezing more than $2.2 billion in funding to Harvard University after the school defied the ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

For the first quarter of this year, J&J’s total sales of $21.9 billion was up 4.2% over the start of 2024, when accounting ...

CenExel is the latest CRO to change ownership hands. Boston-based private equity firm BayPine has acquired a majority stake ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Having picked up a pipeline of oncology drugs as part of a merger last year, NAYA Biosciences is reverting back to its ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas of disease. | The companies said they will work together to train ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...